Skip to main content

TriSalus Life Sciences, Inc.

corporate_fare Company Profile

TriSalus Life Sciences, Inc.

TLSI·NASDAQ·Industrial Applications And Services·CIK 0001826667

TriSalus Life Sciences, Inc. is an oncology-focused medical technology business aiming to improve outcomes for patients with solid tumors. The company integrates its innovative delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist. TriSalus's technology addresses two main challenges in treating solid tumors: high intratumoral pressure, which restricts therapeutic delivery, and off-target delivery. Nelitolimod, combined with their technology, specifically targets the immunosuppressive properties of tumor immune cells in liver, pancreas, and other solid tumors. Many solid tumors, particularly desmoplastic tumors like pancreatic ductal adenocarcinoma ("PDAC"), liver tumors, and various other types, have high interstitial fluid pressure and disorganized, leaky blood vessels, which hinder therapeutic penetration and distribution. TriSalus's platform approach, Pressure-Enabled Drug Delivery ("PEDD"), modulates pressure and flow within blood vessels to enhance intravascular therapeutic delivery into tumors, aiming to increase tumor response compared to conventional delivery methods. The company's device business, including PEDD and TriNav, shows potential for growth.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for TLSI at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • TriSalus Life Sciences Exceeds 2025 Revenue Guidance, Projects Strong 2026 Growth

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$45.15M
Net Income
-$39.23M
Diluted EPS
-$1.84
Op. Cash Flow
-$18.01M
Free Cash Flow
-$18.93M
Gross Profit
$38.19M
Operating Income
-$26.95M
Cash & Equivalents
$20.44M
Total Debt
$33.05M
Debt / Equity
-0.98×
Net Margin
-86.9%
Shares Outstanding
50M sh
Source: 10-K · filed 2026-03-05 · accession 0001628280-26-015163
$2.32
52-week range · as of 2026-11-19 $2.17 – $7.95
Market cap
$143.14M
Volume
539.3K (1.9× avg)
3-mo avg 286.6K
Live data · 2026-11-22 09:12 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TLSI - Filings & News (Page 2)

TLSI
Jan 12, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.80
Real-time Price: $2.32 info
Change: -$3.48 (-60%) info
Market Cap: $143.142M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets